e-learning
resources
Amsterdam 2011
Tuesday, 27.09.2011
Experimental pulmonary hypertension
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Caspase inhibition reduces severe pulmonary hypertension in the AdTGF-1β/SU5416 model of angioproliferative pulmonary hypertension and lung fibrosis
L. Farkas, D. Farkas, D. Kraskauskas, J. Gauldie, M. Kolb, N. Voelkel (Richmond, United States Of America; Hamilton, Canada)
Source:
Annual Congress 2011 - Experimental pulmonary hypertension
Session:
Experimental pulmonary hypertension
Session type:
Poster Discussion
Number:
3334
Disease area:
Interstitial lung diseases, Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
L. Farkas, D. Farkas, D. Kraskauskas, J. Gauldie, M. Kolb, N. Voelkel (Richmond, United States Of America; Hamilton, Canada). Caspase inhibition reduces severe pulmonary hypertension in the AdTGF-1β/SU5416 model of angioproliferative pulmonary hypertension and lung fibrosis. Eur Respir J 2011; 38: Suppl. 55, 3334
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Macitentan reduces progression of TGF-ß1-induced pulmonary fibrosis and pulmonary hypertension
Source: Eur Respir J, 52 (2) 1701857; 10.1183/13993003.01857-2017
Year: 2018
Acute exacerbations and pulmonary hypertension in advanced idiopathic pulmonary fibrosis
Source: Eur Respir J 2012; 40: 93-100
Year: 2012
Role of JAK2/STAT3 pathway in vascular function of pulmonary fibrosis patients
Source: International Congress 2015 – Pulmonary hypertension: promising small molecules
Year: 2015
Pulmonary hypertension in patients with idiopathic pulmonary fibrosis
Source: Eur Respir Mon 2012; 57: 148-160
Year: 2012
Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity
Source: Eur Respir J 2005; 26: 586-593
Year: 2005
Pulmonary hypertension in patients with idiopathic pulmonary fibrosis and combined pulmonary fibrosis and emphysema: hemodynamic severity
Source: International Congress 2018 – Pulmonary hypertension in lung diseases and the role of the right ventricle
Year: 2018
Treatment of pulmonary hypertension in chronic obstructive pulmonary disease
Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-48-0, page=313
Year: 2006
Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome
Source: Eur Respir J 2010; 35: 105-111
Year: 2010
The impact of emphysema in pulmonary fibrosis
Source: Eur Respir Rev 2013; 22: 153-157
Year: 2013
Nintedanib has acute pulmonary vasodilatory effects in transgenic Fra2 mice with spontaneous progressive pulmonary hypertension and lung fibrosis.
Source: International Congress 2019 – Translational aspects of idiopathic pulmonary fibrosis
Year: 2019
Pulmonary arterial hypertension in combined pulmonary emphysema and fibrosis
Source: Annual Congress 2005 - Pulmonary arterial hypertension diagnosis and therapy
Year: 2005
Accelerated ageing in idiopathic pulmonary fibrosis and pulmonary hypertension
Source: International Congress 2018 – Accelerated ageing in lungs
Year: 2018
First histopathological evidence of irreversible pulmonary vascular disease in dasatinib-induced pulmonary arterial hypertension
Source: Eur Respir J, 51 (3) 1701694; 10.1183/13993003.01694-2017
Year: 2018
Pulmonary hypertension in sickle cell disease
Source: Annual Congress 2007 - ACCP1 - Pulmonary hypertension in sickle cell disease
Year: 2007
The effect of lung diseases on pulmonary hypertension and the effect of pulmonary hypertension on the lung
Source: Virtual Congress 2021 – Pulmonary hypertension in the COVID-19 pandemic and beyond
Year: 2021
Pulmonary hypertension in chronic lung disease and hypoxia
Source: Eur Respir J, 53 (1) 1801914; 10.1183/13993003.01914-2018
Year: 2019
Treatment with sildenafil for pulmonary hypertension in pulmonary fibrosis
Source: Eur Respir J 2005; 26: Suppl. 49, 562s
Year: 2005
Right ventricular dysfunction in pulmonary hypertension with combined pulmonary fibrosis and emphysema syndrome
Source: Annual Congress 2013 –Pulmonary circulation: clinical diagnosis, imaging, biomarkers and treatment
Year: 2013
Pulmonary hypertension in interstitial lung disease
Source: Eur Respir J 2008; 31: 1357-1367
Year: 2008
Pulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplant
Source: Eur Respir J 2007; 30: 715-721
Year: 2007
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept